p53-dependent inhibition of trxR1 contributes to the tumor-specific induction of apoptosis by RITA

Cell Cycle

Volumn 8, Issue 21, 2009, Pages 3584-3591

  Hedström, Elisabeth ^a   Eriksson, Sofi ^a   Zawacka Pankau, Joanna ^a,b   Arnér, Elias S J ^a   Selivanova, Galina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Apoptosis; Cancer; p53 dependent; RITA; ROS; Thioredoxin reductase 1

Indexed keywords

AURANOFIN; DIMER; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THIOPHENE; THIOREDOXIN REDUCTASE 1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; COVALENT BOND; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR MECHANICS; OXIDATIVE STRESS; SENSITIZATION; TUMOR CELL;

EID: 70449730274     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.21.9977     Document Type: Article

References (50)

1. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-1334 (Pubitemid 44960417)
2. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-665 (Pubitemid 46232887)
3. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-660 (Pubitemid 46232886)
4. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med 2004; 10:1321-1328 (Pubitemid 40022713)
5. Zawacka-Pankau J, Grinkevich V, Riddarstråle K, Okorokov AL, Hossain S, Larsson L-G, et al. Manuscript in preparation.
6. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15:171-183
7. Grinkevich V, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15:441-453
8. Cheng Q, Sandalova T, Lindqvist Y, Arner ES. Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 2009; 284:3998-4008.
9. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 1996; 93:6146-6151 (Pubitemid 26190818)
10. Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties and thioredoxin reductase activity. Proc Natl Acad Sci USA 1996; 93:1006-1011 (Pubitemid 26054364)
11. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267:6102-6109
12. Nordberg J, Arner ES. Reactive oxygen species, antioxidants and the mammalian thioredoxin system. Free Radic Biol Med 2001; 31:1287-1312 (Pubitemid 33145299)
13. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006; 16:420-426
14. Rundlof AK, Arner ES. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 2004; 6:41-52.
15. Hatfield DL, Yoo MH, Carlson BA, Gladyshev VN. Selenoproteins that function in cancer prevention and promotion. Biochim Biophys Acta 2009.
16. Hintze KJ, Wald KA, Zeng H, Jeffery EH, Finley JW. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J Nutr 2003; 133:2721-2727 (Pubitemid 37099751)
17. Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, Kunimoto M, et al. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 2005; 203:529-537 (Pubitemid 40629015)
18. Gan L, Yang XL, Liu Q, Xu HB. Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells. J Cell Biochem 2005; 96:653-664 (Pubitemid 41504662)
19. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006; 281:13005-13008
20. Kim IS, Jin JY, Lee IH, Park SJ. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 2004; 142:749-755
21. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007; 42:872-881 (Pubitemid 46274171)
22. Simon TM, Kunishima DH, Vibert GJ, Lorber A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res 1981; 41:94-97 (Pubitemid 11218799)
23. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 2007; 104:12288-12293 (Pubitemid 47206130)
24. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005; 39:696-703. (Pubitemid 41112110)
25. Becker K, Gromer S, Schirmer RH, Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000; 267:6118-6125 (Pubitemid 30775306)
26. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4:6-13. (Pubitemid 41350919)
27. Nguyen P, Awwad RT, Smart DD, Spitz DR, Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 2006; 236:164-174 (Pubitemid 44262309)
28. Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, Moos PJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 2006; 27:2538-2549 (Pubitemid 44884113)
29. Ravi D, Muniyappa H, Das KC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. The Journal of biological chemistry 2005; 280:40084-40096 (Pubitemid 41779143)
30. Yu MK, Moos PJ, Cassidy P, Wade M, Fitzpatrick FA. Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes. J Biol Chem 2004; 279:28028-28035 (Pubitemid 38900073)
31. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999; 274:35809-35815
32. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA 2002; 99:14548-14553
33. Seemann S, Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 2005; 24:3853-3863 (Pubitemid 40896397)
34. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nature Med 2005; 11:1306-1313 (Pubitemid 41752911)
35. Sawada O, Ishida T, Horiike K. Frontal gel chromatographic analysis of the interaction of a protein with selfassociating ligands: aberrant saturation in the binding of flavins to bovine serum albumin. J Biochem 2001; 129:899-907. (Pubitemid 32587096)
36. Fojo T. Commentary: Novel therapies for cancer: why dirty might be better. Oncologist 2008; 13:277-283 (Pubitemid 351679902)
37. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003; 7:215-234 (Pubitemid 36512022)
38. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 1998; 273:20096-20101 (Pubitemid 28377564)
39. Arner ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001; 31:1170-1178 (Pubitemid 33052492)
40. Fritz-Wolf K, Urig S, Becker K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J Mol Biol 2007; 370:116-127 (Pubitemid 46817572)
41. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci USA 2001; 98:9533-9538 (Pubitemid 32769338)
42. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 2003; 278:15966-15972 (Pubitemid 36799715)
43. Anestal K, Prast-Nielsen S, Cenas N, Arner ES. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS ONE 2008; 3:1846. (Pubitemid 351943821)
44. Cox AG, Brown KK, Arner ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 2008; 76:1097-1109
45. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51:794-798
46. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS letters 1995; 358:1-3.
47. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007; 96:2181-2196 (Pubitemid 47477879)
48. Rengby O, Johansson L, Carlson LA, Serini E, Vlamis-Gardikas A, Karsnas P, et al. Assessment of production conditions for efficient use of Escherichia coli in highyield heterologous recombinant selenoprotein synthesis. Appl Environ Microbiol 2004; 70:5159-5167
49. Arner ES, Zhong L, Holmgren A. Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol 1999; 300:226-239 (Pubitemid 28500599)
50. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med; In press.